A molecular, hybrid imaging approach accurately detects malignant brain tumors while also preventing unnecessary invasive procedures, recently published research suggests.
Combined PET/MRI scanning with radiopharmaceuticals such as 18F-fluorethyl tyrosine (18F-FET) has proven to enhance diagnostic performance, but there’s less evidence such imaging impacts clinical decision-making. German researchers tested the approach in patients with brain tumors, reporting positive results.
Further studies considering these aspects might evaluate finally if 18F-FET PET/MR as a hybrid modality qualifies for evidence-based use in clinical routine.
Read the full article: https://www.healthimaging.com/topics/molecular/petmri-brain-tumor-patients-unnecessary-treatment
